Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis

Changhoon Yoo1, Sang Soo Lee2, Ki Byung Song3, Jae Ho Jeong1, Jaewon Hyung1, Do Hyun Park2, Tae Jun Song2, Dong Wan Seo2, Sung Koo Lee2, Myung-Hwan Kim2, Seung Soo Lee2, Jin Hee Kim2, Hyung-seung Jin5, Jin-hong Park6, Dae Wook Hwang3, Jae Hoon Lee3, Woohyung Lee3, Heung-Moon Chang1, Kyu-pyo Kim1, Baek-Yeol Ryoo1 and Song Cheol Kim3

BACKGROUND: Patients with borderline resectable pancreatic cancer (BRPC) have poor prognosis with upfront surgery. Methods: This was a single-arm Phase 2 trial for clinical and biomarker analysis. The primary endpoint is 1-year progression-free survival (PFS) rate. Patients received 8 cycles of neoadjuvant modified (m) FOLFIRINOX. Up to 6 cycles of gemcitabine were given for patients who underwent surgery. Plasma immune cell subsets were measured for analysing correlations with overall survival (OS).

RESULTS: Between May 2016 and March 2018, 44 chemotherapy- and radiotherapy-naïve patients with BRPC were included. With neoadjuvant mFOLFIRINOX, the objective response rate was 34.1%, and curative-intent surgery was done in 27 (61.4%) patients. With a median follow-up duration of 20.6 months (95% confidence interval [CI], 19.7–21.6 months), the median PFS and OS were 12.2 months (95% CI, 8.9–15.5 months) and 24.7 months (95% CI, 12.6–36.9), respectively. The 1-year PFS rate was 52.3% (95% CI, 37.6–67.0%). Higher CD14+ monocyte (quartile 4 vs 1–3) and lower CD69+γδT cell(γδTCR+/CD69+) levels (quartiles 1–3 vs 4) were significantly associated with poor OS (p = 0.045 and p = 0.043, respectively).

CONCLUSIONS: Neoadjuvant mFOLFIRINOX followed by postoperative gemcitabine were feasible and effective in BRPC patients. Monocyte and γδ T cells may have prognostic implications for patients with pancreatic cancer. ClinicalTrials.gov identifier: NCT02749136.
METHODS

Patients
This was a single-centre, single-arm, Phase 2 trial. Patients with cytologically or histologically proven pancreatic ductal adenocarcinoma were prospectively enrolled if they met the following inclusion criteria: radiographically documented borderline resectable status according to the National Comprehensive Cancer Network (NCCN) criteria determined by academic gastrointestinal radiologists; Eastern Cooperative Oncology Group performance status (ECOG) 0 or 1; no prior chemotherapy or radiotherapy for pancreatic cancer; and adequate bone marrow, renal, and hepatic function. Patients with adenocarcinoma or neuroendocrine carcinoma and those with evidence of distant metastasis based on computed tomography (CT), magnetic resonance imaging (MRI), or 18F-fluoro-2-deoxyglucose (FDG)–positron emission tomography (PET–CT), were excluded. In this study, baseline 18F-FDG-PET–CT was mandatory to exclude the distant metastases based on the findings from the previous report. This study was approved by the Asan Medical Center Institutional Review Board (approval number: 2016-0313). All patients provided written informed consent.

Treatment
Neoadjuvant mFOLFIRINOX. A total of 8 cycles of mFOLFIRINOX was administered every 14 days prior to surgery. Fluorouracil was administered as a 2400 mg/m² continuous infusion for 46 h. Leucovorin 400 mg/m², oxaliplatin 85 mg/m², and irinotecan 150 mg/m², were administered on day 1. Primary granulocyte-colony stimulating factor (G-CSF) support was not allowed. Dose interruptions and reductions in response to the adverse events (AEs) were predefined in the protocol. Response evaluations using CT or MRI of the abdomen and pelvis were performed every 4 cycles of mFOLFIRINOX.

Surgery. After 8 cycles of mFOLFIRINOX, imaging findings (CT, MRI, and FDG-PET–CT) were reviewed for surgical resectability by a multidisciplinary team, including pancreatobiliary surgeons, gastroenterologists, radiologists, medical oncologists, and radiation oncologists. For patients considered to have resectable tumours after the review, surgery was performed 4–6 weeks after the last dose of mFOLFIRINOX. The extent of surgical resection was decided by attending surgeons. Pathologic findings, including margin status and nodal status, were graded by institutional standards, which followed the guidelines of the American Joint Committee on Cancer, 8th edition. R1 resection was defined as the microscopic evidence of tumour within 1 mm of a resection margin. For patients whose tumours remained unresectable after 8 cycles, mFOLFIRINOX was continued until disease progression or unacceptable toxicity. For these patients, radiotherapy such as concurrent chemoradiotherapy or stereotactic body radiotherapy therapy was also permitted.

Postoperative gemcitabine. For patients who underwent surgical resection, 3 cycles of gemcitabine were administered at 1000 mg/m² as a 30-min weekly infusion for 3 consecutive weeks every 4 weeks. At the discretion of the attending physician, up to 6 cycles of gemcitabine were allowed. During postoperative gemcitabine administration, CT scans and serum CA 19-9 measurements were performed every 3 cycles.

Radiotherapy. Preoperative radiotherapy was not administered in this study. Postoperative concurrent chemoradiotherapy with intravenous fluorouracil was administered for patients with R1 resection following the completion of planned postoperative gemcitabine.

Follow-up. For patients who underwent surgery, CT scans and serum CA 19-9 measurements were performed every 3 months for the first 2 years, then every 6 months for the subsequent 3 years. For patients who did not undergo surgery after preoperative mFOLFIRINOX, CT scans and serum CA 19-9 measurements were conducted every 4 cycles of mFOLFIRINOX for patients treated with mFOLFIRINOX, or every 2 months for patients who discontinued mFOLFIRINOX without disease progression. Additional imaging studies were conducted whenever clinically indicated.

Biomarker analysis
For biomarker analysis, 15 mL of blood was collected at baseline and at the time of each disease evaluation. Peripheral blood mononuclear cells (PBMCs) were obtained by standard density gradient centrifugation. To evaluate the prognostic implications of immune cells, multicolour flow cytometry analyses using the CytoFLEX flow cytometry platform (Beckman Coulter, Brea, CA) were performed to determine the proportions of different immune cell populations in the PBMCs. Panels for multicolour flow cytometry included CD3 (UCHT1; BioLegend, San Diego, CA), CD4 (OKT4; BioLegend), CD8 (SK1; BioLegend), CD14 (6D3; BioLegend), CD11c (3.9; BioLegend), CD56 (5.1H11; BioLegend), y0 TCR (B1; BioLegend), HLA-DR (L243; BioLegend), CD69 (FN50; BioLegend), FoxP3 (236A-E7; ebioscience, San Diego), PD-1 (EH12.2H7; BioLegend), LAG-3 (11C3C65; BioLegend), CTLA-4 (L3D10; BioLegend), and TIGIT (A15153G; BioLegend).

Blinded central image review
An independent central imaging review for borderline resectable status was not mandatory for the enrolment. After patient enrolment was completed, blinded baseline imaging data were subsequently collected and reviewed centrally by two academic pancreatobiliary radiologists (S.S.L. and J.H.K.) for disease extent according to the NCCN criteria.

Statistical analysis
Based on the results of our previous BRPC study, the 1-year progression-free survival (PFS) rate was estimated to be 30% (P0) with gemcitabine-based neoadjuvant chemotherapy. With neoadjuvant mFOLFIRINOX, the 1-year PFS rate was estimated to improve to 50% (P1). To detect this difference with a 2-sided alpha of 0.05 and a power of 80%, 39 patients were required. Assuming a 10% of drop-out rate, a total of 44 patients were required for this study. PFS was defined as the time between the start of first cycle of neoadjuvant mFOLFIRINOX and disease progression defined by the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) or any cause of death, whichever occurred first. Overall survival (OS) was defined as the period from the start of the first cycle of neoadjuvant mFOLFIRINOX until death from any cause. Tumour responses were graded by the treating investigators according to RECIST v1.1.

Analyses of efficacy outcomes were based on the full analysis set (FAS), which consisted of all patients who received at least one dose of study drug. The safety set consisted of all patients who received at least one dose of study drug and had at least one valid post-baseline safety assessment. AEs were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. The Kaplan–Meier method was used to estimate PFS and OS, with surviving patients censored at the time of last follow-up. For exploratory analyses, the log-rank test and cox-proportional hazards regression model were used to evaluate the association with survival outcomes. Multivariate analysis was not performed because of small sample size. A two-sided P value < 0.05 was considered significant for all statistical analyses. This study is registered in ClinicalTrials.gov (NCT02749136).

RESULTS
Patient characteristics
Among the 45 patients who were screened for this study between May 2016 and March 2018, a total of 44 patients were enrolled and received study treatment (Fig. 1). The patients’ baseline characteristics are shown in Table 1.
characteristics are summarised in Table 1. The median age was 60 years (range, 35–76), and 59.1% of patients were male. The most common primary tumour site was the head of pancreas (n = 26, 59.1%), followed by the body (n = 14, 31.9%) and tail (n = 2, 4.5%). Major vein and artery invasion were noted in 20 (45.5%) and 6 (13.6%) patients, respectively, and 18 (40.9%) patients had involvement of both major veins and arteries. According to the blinded central image review, 35 (79.5%) and 9 (20.5%) patients were classified to have BRPC and LAUPC, respectively.

Among the 44 patients who received neoadjuvant mFOLFIRINOX, 27 (61.4%) underwent curative-intent surgery (Fig. 1). The most common reasons for forgoing surgery were insufficient tumour response for resection without disease progression (n = 11), and progressive disease (n = 5, 3 new distant metastasis and two local progression). One patient refused surgery despite conversion to resectable disease after mFOLFIRINOX. Except for 1 patient who experienced postoperative fatigue, 26 (59.3%) patients received postoperative gemcitabine. Among 12 patients who remained unresectable after 8 cycles of mFOLFIRINOX, 3 and 4 patients received radiotherapy before and after progression on mFOLFIRINOX, respectively.

### Efficacy
With neoadjuvant mFOLFIRINOX, partial responses were achieved in 15 (34.1%) patients, and no patients had a complete response, indicating an objective response rate (ORR) of 34.1% (Table 2). Stable disease and progressive disease were the best responses in 28 (63.6%) and 1 (2.3%) patients, respectively.

With a median follow-up duration of 20.6 months (95% CI, 19.7–21.6 months), the median PFS and OS were 12.2 months (95% CI, 8.9–15.5 months) and 24.7 months (95% CI, 12.6–36.9), respectively (Fig. 2a). The 1- and 2-year PFS rates were 52.3% (95% CI, 37.6–67.0) and 20.2% (95% CI, 7.3–33.1), respectively. The 1- and 2-year OS rates were 68.2% (95% CI, 54.5–81.9%) and 50.8% (34.5–67.1%), respectively.

The details of the surgical findings for the 27 patients who underwent surgery are summarised in Table 3. While there was no patient with R2 resection, 22 (81.5%) patients achieved microscopic complete (R0) resection, and 5 (18.5%) patients had microscopic residual disease (R1 resection). According to the AJCC 8th edition, 24 (88.9%) and 3 (11.1%) patients had T1/T2 or T3 stage, respectively. Lymph node metastasis was negative in 17 (63.0%) patients, and 8 (29.6%) and 2 (7.4%) patients had N1 and N2 stage, respectively. Major vein and artery resection were performed in 11 (40.7%) and 6 (22.2%) patients, respectively. For patients who underwent surgery, median PFS and OS were significantly better than for those who did not (PFS, median 14.8 months [95% CI, 12.6–16.9 months] vs 7.4 months [95% CI, 5.8–9.0 months], P < .001; OS, not reached vs 9.0 months [95% CI, 6.5–11.3 months], P < .001; Fig. 2b, c).
The results of the analyses for the association between survival outcomes and clinical characteristics are listed in Table 4. Objective response (CR or PR) to preoperative mFOLFIRINOX was associated with better OS compared with the response of stable disease or progressive disease (median 26.2 months [95% CI, 22.6–29.8 months] vs 13.8 months [95% CI, 9.7–17.9 months]; \( P = 0.046 \)), although the relationship between response and PFS was not statistically significant (median 14.8 months [95% CI, 12.5–17.0 months] vs 9.8 months [95% CI, 6.7–12.9 months]; \( P = 0.09 \); Supplementary Fig. 1A, B). Primary tumour site was also significantly associated with survival outcomes (head vs body/tail; PFS, median 14.1 months [95% CI, 13.1–17.0 months] vs 7.5 months [95% CI, 4.9–10.0 months]; \( P = 0.02 \); and OS, median 26.2 months [95% CI, not assessable] vs 11.7 months [95% CI, 5.9–17.4 months]; \( P = 0.02 \); Supplementary Fig. 1C, D). Sex, age (<60 years vs ≥60 years) and baseline CA 19-9 level (within vs > upper normal range) were not associated with either PFS or OS (all for \( P > 0.05 \)).

Between patients with BRPC and LAUPC redefined by the blinded central image review, there were no statistical differences in terms of conversion surgery rates (62.9% [22/35] vs 55.6% [5/9]; \( P = 0.72 \), ORR (31.4% vs 44.4%, \( P = 0.76 \), PFS (median 13.0 months [95% CI, 9.0–17.1 months] vs 12.2 months [95% CI, 10.7–13.8 months]; \( P = 1.00 \), and OS (median 22.2 months [95% CI, not assessable] vs 24.7 months [95% CI, 2.4–47.1 months]; \( P = 0.66 \) (Supplementary Fig. 1E, F).

After surgery, 19 (70.4%) of 27 patients experienced recurrence, with a median disease-free survival (DFS) from surgery of 10.4 months (95% CI, 9.2–11.6 months). Median OS from surgery was not reached, and the OS rate at 2 years after surgery was 54.4% (Table 2 and Supplementary Fig. 2). Pattern of recurrences were as follows: 11 (57.9%) at distant sites, 8 (42.1%) at local sites, and 3 (15.8%) at both local and distant sites. The liver was the most common recurrence site (n = 9, 47.4%), followed by peritoneum (n = 5, 26.3%), lymph nodes (n = 3, 15.8%) and lung (n = 3, 15.8%). Median DFS from surgery was significantly associated with resection margin status (R0, 10.7 months [95% CI, 6.7–14.8 months] vs R1, 4.0 months [95% CI, 3.4–4.6 months]; \( P = 0.004 \)) and T stage (T1/T2, 10.7 months [95% CI, 8.1–13.3 months] vs T3, 4.0 months [95% CI, 0.0–8.8 months]; \( P < 0.001 \), while tumour differentiation and lymph node metastasis were not associated with median DFS from surgery (\( P = 0.58 \) and \( P = 0.38 \), respectively).

Immune cell biomarker analysis

Flow cytometry analysis of PBMC was available for 31 (70.5%) patients. In the correlation analysis between baseline immune cell subsets and OS, higher CD14+ monocyte (quartile 4 vs quartiles 1–3) and lower CD69+ γδ T cell (γδ TCR+/CD69+) levels (quartiles 1–3 vs quartile 4) were significantly associated with poor OS (\( P = 0.045 \) and \( P = 0.043 \), respectively) (Fig. 3).

Safety

Doses of mFOLFIRINOX were interrupted and reduced for 29 (65.9%) and 30 (68.2%) patients, respectively. Three (6.8%) patients discontinued mFOLFIRINOX within 8 cycles due to AEs. The most common grade 3–4 adverse events with mFOLFIRINOX were neutropenia (n = 24, 54.5%), anaemia (6, 13.6%), and nausea (5, 11.4%) (Supplementary Table 1). G-CSF was administered to 20 patients (45.5%) during mFOLFIRINOX treatment. Relative dose intensities of oxaliplatin, irinotecan, and 5-FU were at least 75% during mFOLFIRINOX (Supplementary Table 2). In patients who received postoperative gemcitabine (n = 26), a median of 5 cycles (range, 1–6 cycles) were administered, and doses of gemcitabine were interrupted and reduced for 10 (38.5%) and 16 (61.5%) patients, respectively. The most common grade 3–4 AEs with postoperative gemcitabine were neutropenia (n = 14, 53.8%) and thrombocytopenia (n = 3, 11.5%). The relative dose intensity of gemcitabine was maintained at least 78% within 3 cycles (Supplementary Table 3).

---

**Table 3.** Details of surgery and pathological outcomes of resected patients.

| Variables                  | Total (n = 27) |
|----------------------------|---------------|
| Procedure                  |               |
| Pancreatoduodenectomy      | 17 (63.0%)    |
| Subtotal/distal pancreatectomy | 9 (33.3%)   |
| Total pancreatectomy       | 1 (3.7%)      |
| Margin status              |               |
| R0 resection               | 22 (81.5%)    |
| R1 resection               | 5 (18.5%)     |
| Major vessel resection     |               |
| Vein resection             | 11 (40.7%)    |
| Artery resection           | 6 (22.2%)     |
| T stage (AJCC 8th)         |               |
| T1                         | 7 (25.9%)     |
| T2                         | 17 (63.0%)    |
| T3                         | 3 (11.1%)     |
| T4                         | 0             |
| N stage (AJCC 8th)         |               |
| N0                         | 17 (63.0%)    |
| N1                         | 8 (29.6%)     |
| N2                         | 2 (7.4%)      |
| Tumour differentiation     |               |
| Well differentiated        | 4 (14.8%)     |
| Moderately differentiated  | 21 (77.8%)    |
| Poorly differentiated      | 2 (7.4%)      |

AJCC American Joint Committee on Cancer.

---

**Fig. 2** Survival outcomes. PFS and OS for overall patients (a), PFS according to the surgery (b) and OS according to the surgery (c). PFS, progression-free survival; OS, overall survival.

---

Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in… C Yoo et al.
DISCUSSION

In this study, perioperative chemotherapy consisting of 8 cycles of neoadjuvant mFOLFIRINOX and 6 cycles of postoperative gemcitabine was feasible for BRPC/LAUPC patients. The rate of conversion surgery was 61.4%, and the 1-year PFS rate was 52.3%, which indicates that this study met its primary endpoint. Median disease-free survival after surgery was 18.0 months and 22.2 months, respectively. In 27 patients who underwent surgery after mFOLFIRINOX, 70.4% of patients experienced recurrence, and the median PFS and OS were 18.0 months and 22.2 months, respectively.

In this study, patients received gemcitabine monotherapy after surgery, because this study was designed and conducted before the data of ESPAC-04 and PRODIGE trials, which demonstrated a survival benefit with postoperative gemcitabine plus capcitabine and mFOLFIRINOX as postoperative chemotherapy for resected pancreatic cancer. In 27 patients who underwent surgery after mFOLFIRINOX, 70.4% of patients experienced recurrence, and the median disease-free survival after surgery was 10.4 months. Considering the high recurrence rates even among patients who underwent curative-intent surgery, more effective adjuvant chemotherapy regimens, such as gemcitabine plus capcitabine or mFOLFIRINOX should be used for medically fit patients following the neoadjuvant mFOLFIRINOX and surgery. The optimal duration and regimen of postoperative chemotherapy for patients who undergo conversion surgery after neoadjuvant mFOLFIRINOX should be defined in future studies.

As prognostic factors, surgical resection and better response to postoperative gemcitabine plus capecitabine and mFOLFIRINOX should be considered for patients following the neoadjuvant mFOLFIRINOX and surgery. The optimal duration and regimen of postoperative chemotherapy for patients who undergo conversion surgery after neoadjuvant mFOLFIRINOX should be defined in future studies.

As prognosis factors, surgical resection and better response to postoperative gemcitabine plus capecitabine and mFOLFIRINOX should be considered for patients following the neoadjuvant mFOLFIRINOX and surgery. The optimal duration and regimen of postoperative chemotherapy for patients who undergo conversion surgery after neoadjuvant mFOLFIRINOX should be defined in future studies.

As prognosis factors, surgical resection and better response to postoperative gemcitabine plus capecitabine and mFOLFIRINOX should be considered for patients following the neoadjuvant mFOLFIRINOX and surgery. The optimal duration and regimen of postoperative chemotherapy for patients who undergo conversion surgery after neoadjuvant mFOLFIRINOX should be defined in future studies.
were not associated with clinical outcomes in this study. Interestingly, there was no difference in terms of PFS and OS between BRPC and LAUPC in our study. This in line with the results of a recent patient-level meta-analysis, which found no difference in median OS between BRPC and LAUPC.

Despite recent advances in neoadjuvant therapy using mFOLFIRINOX in BRPC, further improvements in its efficacy are needed considering that only two-thirds of patients undergo surgery and more than half of patients experience recurrence even after surgery less than 2 years postoperatively. In our study, the most common reason for forgoing surgery (11 of 17 patients) was insufficient tumour response for surgery without tumour progression, and 42.1% of patients whose disease relapsed after curative-intent surgery had local recurrence only. These data suggest the potential benefits of additional preoperative or postoperative radiotherapy to mFOLFIRINOX-based neoadjuvant therapy for BRPC and LAUPC. This approach may improve the local tumour response and surgical resection rates associated with better survival outcomes. A randomised Phase 2 trial (ALLIANCE A021501 trial) comparing 8 cycles of mFOLFIRINOX and 7 cycles of mFOLFIRINOX followed by hypofractionated radiotherapy is ongoing for BRPC of the head of pancreas, and this will reveal the implications of radiotherapy in the era of modern chemotherapy for localised pancreatic cancer.15

In our biomarker analysis using immune cell subsets from baseline PBMC samples, high monocyte and low γδ T cell levels were significantly associated with worse OS. The negative prognostic implication of monocytes has been reported in multiple cancer types including pancreatic cancer, and the promising efficacy of CCR2 blockade targeting monocytes in combination with FOLFIRINOX suggests the potential role of monocytes in pancreatic cancer.17 γδ T cells are MHC-unrestricted unconventional lymphocytes and known to have protective roles against cancer based on their potent cytotoxicity and interferon-γ production.18 Our results suggest that γδ T cells might play some role in pancreatic cancer; however, γδ T cells as therapeutic targets remains to be further studied, and there is a lack of in vivo proof-of-concept human data.

This study has certain limitations. The study was performed at the single centre and about 20% of patients had LAUPC, despite this study was originally intended to investigate only BRPC. The number of included patients was also too small to validate the predictive marker in the multivariate analysis.

In conclusion, neoadjuvant mFOLFIRINOX followed by postoperative gemcitabine were effective for BRPC patients. Biomarker analyses revealed the potential role of immune cell subsets in pancreatic cancer.

ACKNOWLEDGEMENTS
None.

AUTHOR CONTRIBUTIONS
C.Y. planned the study, collected the data, conducted the statistical analysis, interpreted the results and drafted the paper. S.S.L. planned the study, collected the data, conducted the statistical analysis, interpreted the results and drafted the paper. K.B.S. planned the study, collected the data, conducted the statistical analysis, interpreted the results and drafted the paper. I.J.H. collected the data, interpreted the results and drafted the paper. J.H.L. collected the data, interpreted the results and drafted the paper. W.L. collected the data, interpreted the results and drafted the paper. H.-M.C. collected the data, interpreted the results and drafted the paper. K.K. collected the data, interpreted the results and drafted the paper. B.Y.R. planned the study, collected the data, conducted the statistical analysis, interpreted the results and drafted the paper. S.C.K. planned the study, collected the data, conducted the statistical analysis, interpreted the results and drafted the paper. Study concepts/design: C.Y., S.S.L., K.B.S., B.Y.R. and S.C.K. Data acquisition/data analysis/interpretation: All authors. paper preparation: C.Y., S.S.L., K.B.S., B.Y.R. and S.C.K. All authors revised and approved the paper.

ADDITIONAL INFORMATION
Ethics approval and consent to participate The study was approved by the Institutional Review Board of Asan Medical Center, Seoul, Korea (approval number: 2016-0010) and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. All patients provided written informed consent before enrolment.

Consent to publish Not applicable.

Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request.

Competing interests The authors declare no competing interests.

Funding information This study was supported in part by Boryung Pharmaceutical Co., Ltd, the Bio and Medical Technology Development Program from the National Research Foundation (NRF) that is funded by Korean Ministry of Science, Communications Technology, and Future Planning (MSIP) (NRF-2016M3A9E8941331), the Korean Health Technology R&D Project, Ministry of Health & Welfare (HI14C2640), and a grant (2016-728) from the Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea. The funding sources had no role in study design, collection and analysis of data, or writing of the report.

Supplementary information is available for this paper at https://doi.org/10.1038/s41416-020-0867-x.

Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES
1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A. & Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J. Clin. 68, 394–424 (2018).
2. Oettle, H., Neuhaus, P., Hochhaus, A., Hartmann, J. T., Gellert, K., Ridwelski, K. et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer. JAMA 310, 1473–1479 (2013).
3. Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M. et al. Comparison of adjuvant gemcitabine and capcitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389, 1011–1024 (2017).
4. Conroy, T., Hammel, P., Hebbbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L. et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N. Engl. J. Med. 379, 2395–2406 (2018).
5. Kim, M. P. & Katz, M. H. G. Perioperative therapy for borderline resectable pancreatic cancer: what and when? Ann. Surg. Oncol. 26, 1596–1597 (2019).
6. Petrelli, F., Coinu, A., Borgonovo, K., Cabiddu, M., Ghilardi, M., Lonati, V. et al. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas 44, S15–S21 (2015).
7. National Comprehensive Cancer Network. Pancreatic Adenocarcinoma (Version 1). http://www.nccn.org/Professionals/Physician_Gls/Pdf/Pancreatic.Pdf (Accessed July 11, 2016). March 2016:1–133.
8. Ghaneh, P., Hanson, R., Titman, A., Lancaster, G., Plumpton, C., Lloyd-Williams H. et al. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18F-fluorodeoxy-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography.
scanning in the diagnosis and management of pancreatic cancer. Health Technol. Assess. 22, 1–114 (2018).

9. Campbell, F., Smith, R. A., Whelan, P., Sutton, R., Raraty, M., Neoptolemos, J. P. et al. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology 55, 277–283 (2009).

10. Yoo, C., Kang, J., Kim, K.-P., Lee, J.-L., Ryoo, B.-Y., Chang, H.-M. et al. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. Oncotarget 8, 46337–46347 (2017).

11. Joo, I., Lee, J. M., Lee, E. S., Son, J.-Y., Lee, D. H., Ahn, S. J. et al. Preoperative CT classification of the resectability of pancreatic cancer: interobserver agreement. Radiology 293, 343–349 (2019).

12. Murphy, J. E., Wu, J. Y., Ryan, D. P., Jiang, W., Yeap, B. Y., Drapek, L. C. et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 4, 963–969 (2018).

13. Murphy, J. E., Wu, J. Y., Ryan, D. P., Clark, J. W., Jiang, W., Yeap, B. Y. et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol. 5, 1020–1027 (2019).

14. Janssen, Q. P., Buettner, S., Suker, M., Beurner, B. R., Addeo, P., Bachellier, P. et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J. Natl Cancer Inst. 111, 782–794 (2019).

15. Katz, M. H. G., Ou, F.-S., Herman, J. M., Ahmad, S. A., Wolpin, B., Marsh, R. et al. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer 17, 1–8 (2017).

16. Sierzega, M., Lenart, M., Rutkowska, M., Surman, M., Mytar, B., Matyja, A. et al. Preoperative neutrophil-lymphocyte and lymphocyte-monocyte ratios reflect immune cell population rearrangement in resectable pancreatic cancer. Ann. Surg. Oncol. 24, 808–815 (2017).

17. Nywening, T. M., Wang-Gillam, A., Sanford, D. E., Belt, B. A., Panni, R. Z., Cusworth, B. M. et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 17, 651–662 (2016).

18. Silva-Santos, B., Mensurado, S. & Coffelt, S. B. γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer. Nat. Rev. Cancer 348, 1–13 (2019).